Anuh Pharma Limited engages in the manufacture and sale of bulk drugs and chemicals in India. It offers active pharmaceutical ingredients, including macrolides, anti-TB, anti-malarial, anti-hypertension, expectorant, anti-diabetics, anti-bacterial, anti-gout, anti asthmatics, quinolones, anti biotic, anti platelet, anti-histamines, and intermediates; and corticosteroids, including anti-inflammator...
Anuh Pharma reported revenue of 6.62 billion INR for fiscal year 2025, up 2.2% from fiscal year 2024, and net income of 473.52 million INR. In Q3 2026 (the quarter ended December 31, 2025) revenue was 1.97 billion INR, up 23.6% from a year before. Export was its largest region in fiscal year 2025, with 55% of revenue. Its market capitalization was 8.22 billion INR as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2025; market data as of October 9, 2026.
No profile data available.